Related Experiment Video
Updated: Feb 16, 2026

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
Blockade of Tim-3 binding to phosphatidylserine and CEACAM1 is a shared feature of anti-Tim-3 antibodies that have
Catherine A Sabatos-Peyton1, James Nevin2, Ansgar Brock3
1Exploratory Immuno-oncology, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, MA, USA.
Abstract:
Both in vivo data in preclinical cancer models and in vitro data with T cells from patients with advanced cancer support a role for Tim-3 blockade in promoting effective anti-tumor immunity. Consequently, there is considerable interest in the clinical development of antibody-based therapeutics that target Tim-3 for cancer immunotherapy. A challenge to this clinical development is the fact that several ligands for Tim-3 have been identified: galectin-9, phosphatidylserine, HMGB1, and most recently, CEACAM1. These observations raise the important question of which of these multiple receptor:ligand relationships must be blocked by an anti-Tim-3 antibody in order to achieve therapeutic efficacy. Here, we have examined the properties of anti-murine and anti-human Tim-3 antibodies that have shown functional efficacy and find that all antibodies bind to Tim-3 in a manner that interferes with Tim-3 binding to both phosphatidylserine and CEACAM1. Our data have implications for the understanding of Tim-3 biology and for the screening of anti-Tim-3 antibody candidates that will have functional properties in vivo.
Insights
Blocking Tim-3 (T-cell immunoglobulin and mucin-domain containing-3) is crucial for effective anti-tumor immunity. This study shows that successful cancer immunotherapies targeting Tim-3 interfere with its binding to phosphatidylserine and CEACAM1.
Area of Science:
- Immunology
- Cancer Biology
- Drug Development
Background:
- Tim-3 (T-cell immunoglobulin and mucin-domain containing-3) blockade shows promise in preclinical cancer models and patient T cells for enhancing anti-tumor immunity.
- Clinical development of anti-Tim-3 antibody therapeutics is of significant interest for cancer immunotherapy.
- Multiple Tim-3 ligands (galectin-9, phosphatidylserine, HMGB1, CEACAM1) complicate therapeutic strategies, raising questions about which interactions are critical for efficacy.
Purpose of the Study:
- To investigate the binding properties of functional anti-murine and anti-human Tim-3 antibodies.
- To determine which Tim-3 ligand interactions are affected by efficacious anti-Tim-3 antibodies.
- To inform the development and screening of anti-Tim-3 antibody candidates for cancer immunotherapy.
Main Methods:
- Characterization of anti-murine and anti-human Tim-3 antibodies.
- Assessment of antibody binding to Tim-3.
- Evaluation of the impact of antibody binding on Tim-3 interactions with its ligands, including phosphatidylserine and CEACAM1.
Main Results:
- All tested functional anti-Tim-3 antibodies bind to Tim-3.
- This binding interferes with Tim-3's interaction with both phosphatidylserine and CEACAM1.
- The findings provide insights into the mechanism of action for effective Tim-3 blockade.
Conclusions:
- Effective anti-Tim-3 antibodies function by disrupting Tim-3 binding to specific ligands, notably phosphatidylserine and CEACAM1.
- Understanding these critical receptor-ligand interactions is essential for the rational design and selection of anti-Tim-3 antibody therapeutics.
- This research aids in the development of more effective cancer immunotherapies targeting the Tim-3 pathway.
Related Concept Videos
ortho–para-Directing Activators: –CH3, –OH, –⁠NH2, –OCH3
Piaget's Stage 3 of Cognitive Development
Conservation and Constancy of Quantity
A significant cognitive milestone in the...
Neuromuscular Junction And Blockade
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Self-Efficacy
Antibody Structure
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...

